Venus Remedies (Small Cap - Potential Multibagger) Share Target 2026, 2027 To 2035
|
Venus Remedies Limited |
|||
|
Price: ₹1,883.00 (4.76%) | ||
| 52 Week Low: ₹416.00 52 Week High: ₹1,887.30 |
|||
| Market Capital: 1,270.82 Crore (Small-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Venus Remedies Share Price Target For 2026
- 1.1.1: Venus Remedies Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Venus Remedies Share Price Target For 2027
- 1.2.1: Venus Remedies Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Venus Remedies Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Venus Remedies Brief Company Overview
- 4: Venus Remedies Financial Performance
- 4.0.1: Is Venus Remedies A Good Buy For Long Term?
Venus Remedies, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 1305.9% returns in 5-year showing 22.7% quarterly revenue growth with 5.2% profit margin, making it a potential Multibagger.
To predict the Venus Remedies's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Venus Remedies Share Price Target For 2026
The line chart displays the monthly closing prices of Venus Remedies with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Venus Remedies shares in 2026, see the table below.
Venus Remedies Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 2127.61 (+12.99%) | 123.60% Weekly Fib Ext |
| 2026 Target 2 | 2051.34 (+8.93%) | Volatility: ATR T1 |
| 2026 Target 1 | 1943.34 (+3.2%) | Volatility: BB Upper |
| Current Price | 1883.00 | Venus Remedies's share price as of 15 Jun 2026 |
| Stop Loss 1 | 1714.66 (-8.94%) | Volatility: ATR S1 |
| Stop Loss 2 | 1660.08 (-11.84%) | Trend: EMA9 |
| Stop Loss 3 | 1602.43 (-14.91%) | Volatility: ATR S2 |
Short-Term Technical Outlook
Current Technical Position: Venus Remedies is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹1141.27 serves as the nearest technical reference point.
Historical Returns: 3-month: +106.53% | 6-month: +140.13% | 1-year: +293.07%
Venus Remedies Share Price Target For 2027
The line chart displays the monthly closing prices of Venus Remedies with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Venus Remedies shares in 2027, see the table below.
Venus Remedies Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 2127.61 (+12.99%) | 123.60% Weekly Fib Ext |
| 2027 Target 2 | 2051.34 (+8.93%) | Volatility: ATR T1 |
| 2027 Target 1 | 1943.34 (+3.2%) | Volatility: BB Upper |
| Current Price | 1883.00 | Venus Remedies's share price as of 15 Jun 2026 |
| Stop Loss 1 | 1714.66 (-8.94%) | Volatility: ATR S1 |
| Stop Loss 2 | 1660.08 (-11.84%) | Trend: EMA9 |
| Stop Loss 3 | 1602.43 (-14.91%) | Volatility: ATR S2 |
Long-Term Technical Outlook
52-Week Range Analysis: Venus Remedies is currently trading near its 52-week high of ₹1887.3, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +293.07% | 3-year: +631.88% | 5-year: +1305.94%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Venus Remedies Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,883.00 | ||
| 2026 | ₹2,217.50 | +17.764206054169% | ₹2,250.76 |
| 2027 | ₹3,272.68 | +47.584216459977% | ₹3,321.77 |
| 2028 | ₹4,522.54 | +38.190718310376% | ₹4,590.38 |
| 2029 | ₹6,429.35 | +42.162368934271% | ₹6,525.79 |
| 2030 | ₹8,284.46 | +28.853772154261% | ₹8,408.73 |
| 2031 | ₹10,948.94 | +32.162385961185% | ₹11,113.17 |
| 2032 | ₹13,890.24 | +26.863787727396% | ₹14,098.59 |
| 2033 | ₹15,993.52 | +15.142142972332% | ₹16,233.42 |
| 2034 | ₹20,249.28 | +26.609276757087% | ₹20,553.02 |
| 2035 | ₹26,031.34 | +28.554397983533% | ₹26,421.81 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Venus Remedies Brief Company Overview
Venus Remedies Limited: Pharmaceuticals with a Global Reach Venus Remedies Limited, established in 1989, is a leading pharmaceutical company headquartered in India. Venus Remedies is dedicated to developing, manufacturing, and marketing innovative pharmaceutical products that...
cater to various therapeutic areas including analgesics, anti-diabetics, antibiotics, and oncology. Broad Product Range: Venus Remedies boasts a comprehensive portfolio of pharmaceuticals, including: Anti-infectives Anticoagulants Anti-diabetic drugs Antibiotics Antifungals Antivirals International Presence: Venus Remedies has a global presence, with its products available in over 70 countries.Venus Remedies Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 396.73 Crore | Market valuation of Venus Remedies's shares. |
| Revenue (TTM) | 561.92 Crore | Total revenue generated by Venus Remedies over the past twelve months. |
| Net Income (TTM) | +29.02 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 3.83% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 5.16% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+22.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+108.2% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
8.86 | Company's total debt divided by total shareholder equity. |
| Total Debt | 41.74 Crore | Sum of Venus Remedies's current & long-term financial obligations. |
| Total Cash | 70.75 Crore | Total amount of liquid funds available to Venus Remedies. |
| Beta | 1.07 | Beta is greater than 1 indicating that the Venus Remedies's price is more volatile than the market. |
Is Venus Remedies A Good Buy For Long Term?
Venus Remedies has experienced an impressive 108.2% increase in earnings and a 22.7% jump in revenue. However, the company's debt remains high at Rs. 41.74 crore. With a profit margin of 5.16%, the company's profitability is moderate. While the stock has generated substantial returns in the past, its recent performance has been volatile. Overall, Venus Remedies appears to be a moderately risky investment with the potential for long-term growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
